D47.1

Chronic myeloproliferative disease

Chronic myeloproliferative disease (CMPD), also known as chronic myeloproliferative neoplasms (MPN), refers to a group of clonal hematopoietic stem cell disorders characterized by the proliferation of one or more myeloid lineages (erythroid, granulocytic, and megakaryocytic) in the bone marrow and an increase in peripheral blood cell counts. Under the ICD-10-CM classification, D47.1 serves as the designation for chronic myeloproliferative disease not elsewhere classified, including conditions like idiopathic myelofibrosis and myelosclerosis. These disorders are typically progressive and carry risks of transforming into acute myeloid leukemia (AML) or accelerating into a fibrotic phase. The clinical course is often marked by cytoses, organomegaly, and a predisposition to both thrombotic and hemorrhagic complications. Molecular testing often reveals mutations in the JAK2, CALR, or MPL genes, which lead to constitutive activation of the JAK-STAT signaling pathway, driving autonomous cell growth.

Clinical Symptoms

  • Splenomegaly (enlarged spleen) often causing left upper quadrant pain or fullness
  • Hepatomegaly (enlarged liver)
  • Severe fatigue and malaise
  • Unintentional weight loss
  • Night sweats and low-grade fever
  • Pruritus (itching), especially after exposure to warm water
  • Bone pain
  • Gouty arthritis due to hyperuricemia
  • Easy bruising or bleeding (epistaxis, gingival bleeding)
  • Thrombotic events (deep vein thrombosis, pulmonary embolism, stroke, or myocardial infarction)
  • Microvascular symptoms (headaches, dizziness, visual disturbances, or erythromelalgia)
  • Early satiety due to splenic pressure on the stomach

Common Causes

  • JAK2 V617F somatic mutation (most common etiology)
  • CALR (calreticulin) gene mutations
  • MPL (myeloproliferative leukemia virus oncogene) mutations
  • Acquired somatic mutations in hematopoietic stem cells causing clonal expansion
  • Constitutive activation of the JAK-STAT signaling pathway
  • Environmental exposure to high doses of ionizing radiation
  • Exposure to certain industrial chemicals such as benzene
  • Advanced age (typically diagnosed in the 5th to 7th decades of life)

Documentation & Coding Tips

Distinguish between primary myelofibrosis and secondary myelofibrosis in documentation.

Example: Patient diagnosed with Primary Myelofibrosis, JAK2 V617F mutation positive. Bone marrow biopsy reveals Grade 2 reticulin fibrosis and megakaryocytic atypia. This primary chronic myeloproliferative disease is the principal cause of the patient's current splenomegaly and symptomatic anemia. Clinically distinct from secondary myelofibrosis following polycythemia vera.

Billing Focus: Documentation must specify the primary nature of the myeloproliferative disease to support D47.1 rather than secondary codes like D75.81.

Record specific molecular and genetic markers including JAK2, CALR, and MPL status.

Example: Molecular profiling confirms JAK2 V617F mutation in this patient with chronic myeloproliferative disease. Bone marrow aspirate shows hypercellularity with prominent megakaryocytes. The presence of this driver mutation supports the diagnosis and dictates the use of targeted JAK inhibitor therapy. Monitor for cytopenias and disease progression.

Billing Focus: Specificity in genetic markers justifies the use of high-complexity pathology and molecular CPT codes for initial diagnosis and monitoring.

Explicitly document the presence and severity of constitutional B-symptoms.

Example: Patient with chronic myeloproliferative disease reports significant B-symptoms including night sweats requiring change of linens, unexplained weight loss of 12 pounds over 3 months, and persistent low-grade fevers. These symptoms indicate a high symptom burden and progression of the myeloproliferative process, necessitating more intensive therapeutic intervention.

Billing Focus: Constitutional symptoms support the Medical Decision Making (MDM) complexity for E/M leveling, specifically the number and complexity of problems addressed.

Quantify splenomegaly through physical exam or imaging and link it to the primary diagnosis.

Example: Physical examination reveals massive splenomegaly, with the splenic edge palpable 8 cm below the left costal margin. The patient reports early satiety and abdominal discomfort. This extramedullary hematopoiesis is a direct manifestation of the chronic myeloproliferative disease (D47.1) and is being managed with Ruxolitinib.

Billing Focus: Linking manifestations like splenomegaly to the primary D47.1 code provides a comprehensive clinical picture for medical necessity of treatments.

Specify the grade of bone marrow fibrosis using the 0 to 3 grading scale.

Example: Repeat bone marrow biopsy demonstrates progression to Grade 3 collagen fibrosis (myelofibrosis). There is a marked decrease in trilineage hematopoiesis. The chronic myeloproliferative disease has advanced, leading to worsening pancytopenia. Clinical plan involves evaluating the patient for hematopoietic stem cell transplant.

Billing Focus: Grade of fibrosis provides the clinical evidence required for the specific diagnosis of primary myelofibrosis within the D47.1 category.

Relevant CPT Codes

Related Diagnoses

Hierarchy